Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Departure of a VP
Appointed CFO
Quarterly results
Director comp.
|
|
SCOLR Pharma, Inc. (SCLR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/04/2013 |
8-K
| Quarterly results |
| 10/24/2012 |
8-K
| Entry into a Material Definitive Agreement |
| 06/28/2012 |
8-K
| Form 8-K - Current report |
| 05/10/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 04/05/2012 |
8-K
| Form 8-K - Current report |
| 03/26/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/14/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/08/2012 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 11/10/2011 |
8-K
| Form 8-K - Current report |
| 07/26/2011 |
8-K
| Form 8-K - Current report |
| 07/07/2011 |
8-K
| Form 8-K - Current report |
| 06/16/2011 |
8-K
| Other Events |
| 06/16/2011 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"SCOLR Pharma, Inc. Announces Initial Closing of Private Placement BOTHELL, WA, June 16, 2011 - SCOLR Pharma, Inc. today announced that it has closed the sale of $1 million principal amount of its 8% Senior Secured Convertible Debentures due 2013 in an initial closing of its private offering of up to $1.75 million principal amount of Debentures. The Company may offer additional Debentures, up to the aggregate maximum of $1.75 million, until June 30, 2011, unless extended. The Debentures, together with accrued and unpaid interest thereon, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of Common Stock. Beginning after the date that is six months from the issuance of the Debentures, the Company may cause man..." |
|
| 06/14/2011 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/07/2011 |
8-K
| Form 8-K - Current report |
| 05/09/2011 |
8-K
| Quarterly results|
Docs:
|
"SCOLR Pharma, Inc. First Quarter 2011 Financial Results BOTHELL, WA, May 9, 2011, - SCOLR Pharma, Inc. today reported financial results for the three months ended March 31, 2011 and also provided updates on a number of key corporate objectives. Corporate updates include the following: • The Company amended its lease with the landlord of the Company's principal office in Bothell, Washington. The Company and the landlord agreed to reduce the term of the lease so that it will expire on March 31, 2012 rather than January 31, 2016; to reduce the amount of monthly rent and common area maintenance charges from approximately $38,756 to $11,050; and to forgive all past due amounts for unpaid rent and common area maintenance charges. • Stephen J. Turner, President and Chief Executive Officer, and Ri..." |
|
| 04/27/2011 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"SCOLR Pharma, Inc. Signs New Lease Amendment and Lowers Severance Amounts in Executive Contracts BOTHELL, WA, April 26, 2011,—SCOLR Pharma, Inc. today announced that it has taken two steps in their ongoing initiative to reduce expenses. The Company amended its lease with the landlord of the Company's principal office in Bothell, Washington. The Company and the landlord agreed to reduce the term of the lease so that it will expire on March 31, 2012 rather than January 31, 2016; to reduce the amount of monthly rent and common area maintenance charges from approximately $38,756 to $11,050; and forgive all past due amounts for unpaid rent and common area maintenance charges totaling $63,006. In consideration for agreeing to amend the lease, the landlord is entitled to retain a cash security de..." |
|
| 03/29/2011 |
8-K
| Form 8-K - Current report |
| 03/29/2011 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review |
| 03/14/2011 |
8-K
| Form 8-K - Current report |
| 02/25/2011 |
8-K
| Form 8-K - Current report |
| 12/22/2010 |
8-K
| Form 8-K - Current report |
| 09/29/2010 |
8-K
| Form 8-K - Current report |
| 09/02/2010 |
8-K
| Form 8-K - Current report |
| 06/14/2010 |
8-K
| Form 8-K - Current report |
| 05/06/2010 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 04/29/2010 |
8-K
| Quarterly results |
| 03/24/2010 |
8-K
| Form 8-K - Current report |
| 03/24/2010 |
8-K
| Termination of a Material Definitive Agreement |
| 03/16/2010 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"SCOLR Pharma Acquires the Rights to Nuprin® from CVS BOTHELL, WA, March 16, 2010, - SCOLR Pharma, Inc. today announced that it had acquired rights to the Nuprin® name in connection with sales of ibuprofen. SCOLR paid $180,000 to purchase all right, title and interest of Advanced Healthcare Distributors, LLC to the Nuprin® name, including its portfolio of global registrations . Advanced Healthcare Distributors, LLC is an affiliate of CVS Caremark Corporation. Stephen J. Turner, SCOLR Pharma's President and CEO, said, “Our acquisition of this globally recognized name will provide us with additional opportunities for ibuprofen-based products. We expect that the acquisition will allow us to generate potential near-term sales of immediate release 200 mg ibuprofen tablets, in additio..." |
|
| 02/18/2010 |
8-K
| Entry into a Material Definitive Agreement |
| 01/04/2010 |
8-K
| Entry into a Material Definitive Agreement |
| 11/30/2009 |
8-K
| Form 8-K - Current report |
| 09/01/2009 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
|
|
|